Key result
Having a CMV-positive donor was associated with an increased risk of CMV viremia (P<0.012), while the use of mTOR inhibitors was protective against viremia (P=0.005).
Population
199 heart transplant recipients ≥18 years of age, mean age 52 years, 84% male.
Design
Cohort
Authors
Loading...
May inform CMV risk stratification by donor status and mTOR use in heart transplant recipients; hypothesis-generating and should not yet change practice.
Cohort (n=199)
p-value: p=<0.012
In heart transplant recipients, a CMV-positive donor increases the risk of CMV viremia, whereas the use of mTOR inhibitors appears protective.
Delgado et al. (2010) conducted a cohort in Heart transplant recipients (n=199). Positive donor CMV serostatus and mTOR inhibitors vs. Negative donor CMV serostatus and no mTOR inhibitors was evaluated on CMV viremia (p=<0.012). Having a CMV-positive donor was associated with an increased risk of CMV viremia (P<0.012), while the use of mTOR inhibitors was protective against viremia (P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: